Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.

Autor: Michaelson MD; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., McKay RR; Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Werner L; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Atkins MB; Department of Medical Oncology, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC., Van Allen EM; Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Olivier KM; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Song J; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Signoretti S; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., McDermott DF; Department of Medical Oncology, Beth-Israel Deaconess Medical Center, Boston, Massachusetts., Choueiri TK; Kidney Cancer Center, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Publikováno v: Cancer [Cancer] 2015 Oct 01; Vol. 121 (19), pp. 3435-43. Date of Electronic Publication: 2015 Jun 08.